Our CEO Sam Windsor spoke at Fierce Pharma Biotech week 2025 in Boston.
Platform biotech companies are reshaping pharma’s innovation model - but getting deals done requires more than breakthrough science. In this session, leaders from emerging platform companies shared hard-earned lessons from the dealmaking front lines. Alongside pharma perspectives, they unpacked how they framed value, navigated control, and structured partnerships to preserve upside while building long-term credibility.
The panel discussed:
- How platform biotechs are proving value beyond a single asset—and what that means for deal design.
- How companies approach optionality, equity stakes, and governance to align short-term needs with long-term vision.
- What biotechs wish pharma understood better when it comes to platform risk, valuation, and partnership expectations.
Panelists: Sam Windsor, Hanadie Yousef, Dinesh V. Patel, and Sahm Nasseri